Peginterferon alfa-2a

Specification

• Cat#: THP-0022
• Product Name: Peginterferon alfa-2a
• Description: The product is a modified form of recombinant interferon and is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors.
• Sequences: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
• Species: Human
• Molecular Weight: 60000.0 Da
• Cas No: 198153-51-4
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 180ug/ml

Pharmaceutical Information

• Pharmaceutical Application: Peginterferon alfa-2a
• Applications: The product is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. The product is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who havecompensated liver disease and evidence of viral replication and liver inflammation.
• Examples of Clinical Use: Compensated liver disease
• Pharmacodynamics: The product induces the body's innate antiviral response.
• Mechanism of action: Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.
• Affected organisms: Humans and other mammals
• Targets: Target 1. Interferon alpha/beta receptor 2; Target 2. Interferon alpha/beta receptor 1; Enzyme 1. Cytochrome P450 1A2